Introduction
============

Human beings have long used plants as a medicinal source. Their use has grown more sophisticated with modern chemists using compounds isolated from plants as a basis for generating novel compounds with additional benefits, such as its lower toxicity and potential for combating drug-resistant diseases. Between 1981 and 2010, naturally derived products and their mimics composed an estimated 70% of new chemical compounds reported.[@b1-dti-9-2015-009] Naturally derived compounds with anticancer activity have also been used as the basis for original synthetic analogs, forming their own novel class of chemical compounds.[@b2-dti-9-2015-009]

Mammalian microtubules appear to be a common target for naturally occurring toxic molecules produced by a large number of flora, presumably with the original intent of self-defense. Microtubules are a component of the cytoskeleton, found throughout the cell cytoplasm, which is important in the process of mitosis (ie, cell division). Most microtubule-targeting compounds have been discovered in large-scale screens of natural products[@b3-dti-9-2015-009],[@b4-dti-9-2015-009] ([Table 1](#t1-dti-9-2015-009){ref-type="table"}). Approximately 75% of the available anticancer drugs between 1940 and 2010 were naturally derived products or their mimics. Additionally, of the seven anticancer drugs approved in 2010, almost half of them exert their effects by binding onto microtubules.[@b1-dti-9-2015-009]

One of the biggest success stories of microtubule-targeted compounds from a naturally derived source is Paclitaxel (commercially known as Taxol), a member of the Taxane family. Paclitaxel is extracted from the bark of the Pacific yew tree (*Taxus brevifolia*) and acts as an antimitotic drug, by binding to microtubules, thus stabilizing them and arresting cells in mitosis.[@b5-dti-9-2015-009]--[@b9-dti-9-2015-009] Taxol and its derivatives have successfully been used clinically to treat ovarian cancer, breast cancer, and non-small cell lung cancer for almost 40 years, making Taxol the best-selling anticancer drug currently manufactured. Its success has sparked the search for similar microtubule-stabilizing compounds.

Another class of microtubule-targeted compounds from a naturally derived source is the vinca alkaloids, vincristine and vinblastine, which were initially isolated from the Madagascar periwinkle plant (*Catharanthus roseus*).[@b10-dti-9-2015-009] The vinca alkaloids are microtubule destabilizers and have proven to be particularly effective against hematological malignancies,[@b11-dti-9-2015-009] and their success has generated several semisynthetic derivatives. Semisynthetic and synthetic derivatives may offer advantages over a fully natural source, as the bioactive natural compound may be present only in trace amounts. Natural compounds may instead act as lead compounds, where analogs with higher potencies and lower toxicities may be developed[@b12-dti-9-2015-009],[@b13-dti-9-2015-009] ([Table 2](#t2-dti-9-2015-009){ref-type="table"}). Natural products are ideal as lead compounds as their chemical structures are complex and diverse ([Table 3](#t3-dti-9-2015-009){ref-type="table"}). The biggest study looking into the isolation of compounds with clinical bioactivity, specifically anticancer activity, from natural sources was done by the National Cancer Institute (NCI) of the National Institute of Health in USA from 1960 to 1980.[@b14-dti-9-2015-009] However, it is estimated that \>90% of plant species worldwide remain understudied. Discovery of drug molecules has been limited because of genomic instability and drug resistance characteristics in certain cancer cells.[@b15-dti-9-2015-009] Therefore, modern drug discovery has shifted to personalized treatment of patients, where drugs are selected for specific molecular targets, taking advantage of the vulnerabilities of cancer in a particular patient, leading to increased interest in studying traditional herbs as an alternative source of anticancer drugs because of its multitargeted characteristic.[@b16-dti-9-2015-009]

The Role of the Microtubule in Cell Division
============================================

Microtubules are a class of the cytoskeletal proteins present in all eukaryotic cells. They form long, filamentous, polymeric structures within the cell, composed of α- and β-tubulin heterodimers, of which there are several isotypes.[@b17-dti-9-2015-009] The different isotypes of tubulin in human beings are summarized in [Table 4](#t4-dti-9-2015-009){ref-type="table"}. Microtubules play many roles in eukaryotic cells, including development and maintenance of cell shape,[@b18-dti-9-2015-009] intracellular transport,[@b19-dti-9-2015-009] cell motility,[@b20-dti-9-2015-009],[@b21-dti-9-2015-009] cell signaling,[@b22-dti-9-2015-009] and cell division.[@b23-dti-9-2015-009]

Cell division, or mitosis, is a crucial event in the cell cycle that results in the division of a single cell into two identical daughter cells with the equal distribution of genetic materials ([Fig. 1](#f1-dti-9-2015-009){ref-type="fig"}). During mitosis, the cytoskeleton forms a superstructure called the mitotic spindle, which facilitates many of the cell division processes. Mitosis involves a series of stages. The initial prophase and prometaphase stages are where there is condensation of chromosomes, which then attaches to the mitotic spindle. The chromosomes then align at the equator of the mitotic spindle (metaphase) before the sister chromosomes segregate into daughter cells (anaphase). The final stage is where the chromosomes decondense and the cells divide fully into two daughter cells (telophase). All the stages of mitosis must be regulated for the proper development and function of a multicellular organism. Central to the function of microtubules is the regulation of microtubule dynamics. Microtubule filaments are able to polymerize and depolymerize stochastically within a cell, in what is termed as microtubule dynamicity.[@b24-dti-9-2015-009] Microtubule dynamics are tightly regulated within cells, through the binding of various regulatory proteins, expression of different tubulin isotypes, and posttranslational modifications of tubulin subunits.[@b25-dti-9-2015-009],[@b26-dti-9-2015-009] Dynamic microtubules have a very short half-life of a few minutes, or even seconds, whereas stable microtubules have half-lives of minutes to hours.[@b27-dti-9-2015-009]

During mitosis, microtubules are the main components of the mitotic spindle, where microtubule dynamics are increased significantly.[@b27-dti-9-2015-009],[@b28-dti-9-2015-009] Dynamic microtubules are required for all stages of mitosis: from capturing and congressing chromosomes to the metaphase plate,[@b29-dti-9-2015-009] pulling chromosomes toward opposite poles and initiating anaphase,[@b30-dti-9-2015-009] and finally cytokinesis to complete mitosis.[@b31-dti-9-2015-009],[@b32-dti-9-2015-009] Microtubule-binding compounds may either stabilize microtubules (promoting growth and not supporting shrinkage of the microtubule filament) or destabilize microtubules (promoting shrinkage and not supporting growth of the microtubule filament). Any alterations in microtubule dynamics will affect the different events in mitosis. For example, if microtubule dynamics are suppressed, chromosomes may not be able to congress to the metaphase plate.[@b33-dti-9-2015-009],[@b34-dti-9-2015-009] The presence of a single uncongressed chromosome is enough to induce mitotic arrest.[@b1-dti-9-2015-009] Accordingly, altered microtubule dynamics is among the major causes of mitotic arrest. A cell that is arrested in mitosis for a prolonged time may eventually undergo apoptosis, or programed cell death.[@b35-dti-9-2015-009] At present, most of the drugs used to treat cancer target microtubule dynamics in order to arrest cancerous cells in mitosis.

Microtubules---A Potential Target for Cancer Therapy
====================================================

Unregulated cell division may lead to an overgrowth of cells, as in cancer. The ability to carry out an infinite number of cell divisions is one of the hallmarks of cancer.[@b36-dti-9-2015-009] Blockage of any stage of mitosis may not allow the cells to complete mitosis, resulting in cell cycle arrest and ultimately, cell death. Microtubules represent the best and most successful target thus far identified in cancer treatment.[@b37-dti-9-2015-009]--[@b39-dti-9-2015-009] Cancer cells are sensitive to microtubule poisons that arrest cells in mitosis because they undergo mitosis more frequently than normal cells. At high concentrations, anticancer drugs that target microtubules may act in one of the two ways. Each approach has different effects, including affecting the polymerized microtubule mass, destabilization of microtubules (decreases microtubule mass), and stabilization of microtubules (increases microtubule mass), dependent on the site of binding on the microtubule lattice.[@b40-dti-9-2015-009] The effects of each compound on microtubules are indicated in both [Tables 1](#t1-dti-9-2015-009){ref-type="table"} and [2](#t2-dti-9-2015-009){ref-type="table"}.

Currently, there are two main classes of microtubule-binding anticancer drugs. These are the microtubule destabilizers, such as the Vinca alkaloids,[@b41-dti-9-2015-009]--[@b44-dti-9-2015-009] and microtubule stabilizers that prevent microtubule disassembly without affecting their polymerization, such as the taxanes.[@b6-dti-9-2015-009] However, studies have shown that various microtubule-targeting drugs, irrespective of their effects on polymerized microtubule mass at high concentrations, all suppress microtubule dynamics at lower concentrations, ie, prevent the growth or shrinkage of microtubules without changing the microtubule polymer mass[@b6-dti-9-2015-009],[@b8-dti-9-2015-009],[@b33-dti-9-2015-009],[@b34-dti-9-2015-009],[@b42-dti-9-2015-009]--[@b45-dti-9-2015-009] ([Fig. 2](#f2-dti-9-2015-009){ref-type="fig"}). In this way, changes in microtubule dynamics can be used as an indicator of the efficacy of the anticancer activities of a naturally derived compound.

Conversely, tumors can acquire resistance to microtubule-targeting drugs. Although a discussion on the resistance mechanisms to these drugs is beyond the scope of this review, the possible methods of resistance include multidrug resistance pumps, altered drug binding, altered microtubule assembly, altered tubulin synthesis, and alterations in microtubule-interacting proteins (refer to Fojo and Menefee[@b46-dti-9-2015-009] for a more extensive review).

As with all drugs, the toxic side effects of microtubule-targeting agents must be taken into account. Owing to the physiological functions of microtubules, treatment with microtubule-targeting agents often exhibits myelo-suppression and peripheral neuropathy. The specificity of each compound must therefore be tested. The cancers identified to be susceptible to each drug are illustrated in [Tables 1](#t1-dti-9-2015-009){ref-type="table"} and [2](#t2-dti-9-2015-009){ref-type="table"}.

Conclusion
==========

Mitosis is an important stage of the cell cycle, which is deregulated in cancer, leading to uncontrolled cancer growth. An important facilitator of mitosis is the microtubule cytoskeleton. Hence, many anticancer drugs target the microtubule skeleton in order to arrest cancer cells in mitosis, which eventually leads to cell death. Most of these microtubule-targeting drugs act by suppressing microtubule dynamics, which is particularly important for the microtubule function in mitosis. Interestingly, many of the microtubule-binding anticancer drugs are derived from natural sources, including Taxol and the vinca alkaloids, two very successful classes of anticancer drugs. Therefore, there is great potential for the isolation of compounds with similar microtubule-targeting activities from medicinal plants. Future aims for the development of novel microtubule-binding agents are the development of compounds specific to cancer cells, thereby reducing potential toxic side effects, as well as the development of compounds that are able to overcome current drug-resistant cancers.
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![The process of cell division in mammalian cells. This figure illustrates the different microtubule structures present during different stages of the cell cycle. In the interphase stage of the cell cycle, microtubules (green) emanate out from the microtubule-organizing center, the centrosome (dark blue circle), forming an array that extends toward the cell periphery. During the mitotic stage of the cell cycle, the centrosomes are duplicated and separated to form spindle poles, while the microtubule cytoskeleton is reorganized to form a superstructure called the mitotic spindle. The mitotic spindle is responsible for mitotic events such as chromosome congression and chromosome segregation. Two stages of the mitotic stage of the cell cycle are illustrated---metaphase and anaphase. At metaphase, the mitotic spindle holds sister chromatids (blue) together at the cell equator. At anaphase, the cell elongates the spindle poles move further apart and the sister chromatids move toward the opposite poles. Black arrows indicate the path normally followed by a cell in a cell cycle. When the cell cycle is disrupted at mitosis by tubulin-binding agents, the cell is unable to complete mitosis and follows an alternative pathway (red arrows) where it undergoes mitotic arrest and eventually cell death. All stages of mitosis must be regulated for proper development and function of a multicellular organism. Unregulated mitosis may lead to an overgrowth of cells, as in cancer. The ability to carry out an infinite number of cell divisions is one of the hallmarks of cancer. Blockage of any stage of mitosis may not allow the cells to complete mitosis, resulting in cell cycle arrest and ultimately, cell death.](dti-9-2015-009f1){#f1-dti-9-2015-009}

![Microtubule dynamic instability. The figure illustrates the growth and shrinkage of a single microtubule, with each row representative of a single time point. Microtubules are composed of stable αβ-tubulin heterodimers that are arranged in a head-to-tail fashion, forming a polar structure. Each heterodimer is illustrated as a single circle. Microtubules therefore consist of two distinct ends: the plus (+) end and the minus (−) end. In vivo, the---ends are anchored at the microtubule-organizing centers. The + ends are more dynamic than the---ends, with the microtubule end constantly switching between growth and shrinkage in what is termed dynamic instability. Microtubules are normally very dynamic (top), with tubulin subunits randomly added or lost from both ends. In vivo, microtubule elongation usually occurs in the plus end. When microtubule dynamics are suppressed (for example, through the action of tubulin-binding agents) (bottom), tubulin subunits are rarely added or lost from the microtubule ends.](dti-9-2015-009f2){#f2-dti-9-2015-009}

###### 

Selected compounds originally isolated from natural sources that act on microtubules.

  BIOLOGICALLY ACTIVE COMPOUND(S)AND THEIR STRUCTURE   SCIENTIFIC NAME(S) OF NATURAL SOURCE   MECHANISM OF ACTION ON MICROTUBULES   STATUS AS ANTI-CANCER DRUG                                                            TESTED CANCER TYPES                                                                                                                                                                                                                                                                                                                                                                               REFERENCES
  ---------------------------------------------------- -------------------------------------- ------------------------------------- ------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------
  Paclitaxel                                           *Taxus brevifolia*                     Stabilizes microtubules               In clinical use                                                                       Ovarian cancer, breast cancer, non-small cell lung cancer, advanced Kaposi sarcoma                                                                                                                                                                                                                                                                                                                47,48
  Vinblastine Vincristine                              *Catharanthus roseus*                  Destabilizes microtubules             In clinical use                                                                       Acute lymphoblastic leukaemia, breast cancer, choriocarcinoma, Hodgkin lymphoma, Kaposi sarcoma, Mycosis fungoides, Hodgkin and non-Hodgkin lymphoma, testicular cancer, neuroblastoma, rhaddomycosarcoma, Wilms tumour, bladder cancer, testicular cancer, breast cancer, choriocarcinoma, lung cancer, multiple myeloma, soft tissue sarcoma, brain tumours. Leukaemia, head and neck cancers   10,11,49,50
  Colchicine                                           *Colchicum autumnale*                  Destabilizes microtubules             Failed anti-cancer trials due to toxicity; in clinical use for gout therapy           Hepatocellular carcinoma, multiple myeloma, Hodgkin's lymphoma, chronic lymphatic leukaemia, breast cancer, lung cancer, chronic lymphocytic leukaemia                                                                                                                                                                                                                                            51--53
  Podophyllotoxin                                      *Podophyllum* spp.                     Destabilizes microtubules             In use for the topical treatment of external genital warts                            None                                                                                                                                                                                                                                                                                                                                                                                              43,54,55
  Combretastatins                                      *Combretum caffrum*                    Destabilizes microtubules             Phase I, II clinical trials; Semi-synthetic derivative in Phase III clinical trials   Acute myeloid leukaemia, myelodysplastic syndrome, thyroid cancer, non-small cell lung cancer, various solid tumours                                                                                                                                                                                                                                                                              56
  Noscapine                                            *Papaveraceae* spp.                    Suppresses microtubule dynamics       Phase II clinical trials                                                              Multiple myeloma                                                                                                                                                                                                                                                                                                                                                                                  57

**Note:** Data in this table were obtained from a combination of NCI Drug Dictionary (<http://www.cancer.gov/drugdictionary>), published literature, and company web sites.

###### 

Selected synthetic and semisynthetic compounds originally isolated from natural sources that act on microtubules.

  COMPOUND AND STRUCTURE   ORIGINAL COMPOUND   MECHANISM OF ACTION ON MICROTUBULES   STATUS AS ANTICANCER DRUG                            TESTED CANCER TYPES                                                                                                                                                           REFERENCES
  ------------------------ ------------------- ------------------------------------- ---------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------
  Vindesine                Vinca alkaloids     Destabilizes microtubules             In clinical use                                      Various lung cancers, various haematological malignancies, melanoma, renal cancer, colorectal cancer and breast cancer. Currently in clinical trials for other cancer types   58
  Vinorelbine              Vinca alkaloids     Destabilizes microtubules             In clinical use                                      non-small cell lung cancer, meta-static breast cancer, renal cancer                                                                                                           42,59,60
  Vinflunine               Vinca alkaloids     Destabilizes microtubules             In clinical use                                      Bladder cancer, urethral cancer, ureteral cancer, cancer of the renal pelvis                                                                                                  42
  Docetaxel                Paclitaxel          stabilizes microtubules               In clinical use                                      Breast cancer, gastric cancer, non-small cell lung cancer, prostrate cancer, squamous cell carcinoma of the head and neck, stomach cancer                                     61
  Cabazitaxel              Paclitaxel          stabilizes microtubules               In clinical use                                      Metastatic prostrate cancer                                                                                                                                                   62,63
  Larotaxel                Paclitaxel          stabilizes microtubules               Phase III clinical trials                            Breast cancer, pancreatic cancer, urothelial tract cancer, bladder cancer, various solid tumours                                                                              63
  Tesetaxel                Paclitaxel          stabilizes microtubules               Phase II clinical trials                             Gastric cancer, melanoma, bladder cancer, breast cancer, prostate cancer, various solid tumours                                                                               63
  Ombrabulin               Combrestatin        Destabilizes microtubules             Discontinued, due to insufficient clinical benefit   Soft tissue sarcoma, non-small cell lung cancer, ovarian cancer, various solid tumours                                                                                        55,64
  Fosbretabulin            Combrestatin        Destabilizes microtubules             Phase I and phase II clinical trials                 Ovarian cancer, gastrointestinal neuroendocrine tumours, ovarian epithelial, fallopian tube, and primary peritoneal cancers, gliomas, thyroid cancer                          65
  Crolibulin               Combrestatin        Destabilizes microtubules             Phase I and phase II clinical trials                 Thyroid cancer                                                                                                                                                                66
  Verubulin                Combrestatin        Destabilizes microtubules             Phase I and phase II clinical trials                 Glioblastoma                                                                                                                                                                  66--68

**Note:** Data in this table were obtained from a combination of NCI Drug Dictionary (<http://www.cancer.gov/drugdictionary>), published literature, and company web sites.

###### 

Chemical structures of natural microtubule-targeting compounds and their synthetic and semisynthetic derivatives.

  --
  --

###### 

subtypes and isoforms of microtubules.

  TUBULIN SUBTYPE   ISOTYPE   GENE     LENGTH (AMINO ACIDS)                                                                                             TISSUE DISTRIBUTION                                                                                     PUTATIVE FUNCTION (IF ANY)                                                                              ALTERED EXPRESSION IN CANCERS?
  ----------------- --------- -------- ---------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------- ------------------------------------------------------
  α                 1A        TUBA1A   451                                                                                                              Ubiquitous                                                                                                                                                                                                      No
  1B                TUBA1B    451      Ubiquitous                                                                                                                                                                                                               No                                                                                                      
  1C                TUBA1C    449      Ubiquitous                                                                                                                                                                                                               No                                                                                                      
  3C                TUBA3C    450      Enriched expression in testis, fallopian tube, soft tissues, central nervous system and other selected tissues                                                                                                           Variable expression                                                                                     
  3D                TUBA3D    450      Enriched expression in testis, fallopian tube, soft tissues, central nervous system and other selected tissues   No isoform-specific function identified                                                                 Decreased                                                                                               
  3E                TUBA3E    448      Enriched expression in testis, fallopian tube, soft tissues, central nervous system and other selected tissues                                                                                                           Decreased                                                                                               
  4A                TUBA4A    446      Ubiquitous                                                                                                                                                                                                               No                                                                                                      
  8                 TUBA8     449      Ubiquitous, but enriched in heart muscle, skeletal muscle and testis                                                                                                                                                     Decreased                                                                                               
  β                 1         TUBB1    451                                                                                                              Enriched in haematopoietic cells                                                                        May play a role in microtubule stability, as well as interaction with actin                             Increased on exposure to microtubule-targeting drugs
  2A                TUBB2A    445      Ubiquitous, enriched in brain                                                                                    May play a role in neuronal differentation                                                              Increased in microtubule-targeting drug-resistant cancers                                               
  2B                TUBB2B    445      Ubiquitous, enriched in brain                                                                                    May play a role in neuronal differentation                                                              No                                                                                                      
  3                 TUBB3     450      Mostly expressed in central and peripheral nervous system                                                        May play a role in neuronal differentiation. May help cells cope with oxidative stress                  Overexpressed in aggressive tumours                                                                     
  4A                TUBB4A    444      Highly expressed in brain, moderate levels in testis, very low levels in other tissues                           Occurs in axonemes, may be required for determination of axonemal microtubule structure                 Increased on exposure to microtubule-targeting drugs                                                    
  4B                TUBB4B    445      Ubiquitous                                                                                                       Occurs in axonemes, may be required for determination of axonemal microtubule structure                 No                                                                                                      
  5                 TUBB      444      Ubiquitously expressed with highest levels in spleen, thymus and immature brain                                  Unknown                                                                                                 Unknown                                                                                                 
  6                 TUBB6     446      Ubiquitous, with highest expression in the breast and lung                                                       Unknown                                                                                                 Largely decreased                                                                                       
  8                 TUBB8     444      Ubiquitous, enriched in cliliated cells and lymphoid tissue                                                      Unknown                                                                                                 Unknown                                                                                                 
  γ                 1         TUBG1    451                                                                                                              Ubiquitous                                                                                              Important for nucleation and polarity of microtubules, mostly found in microtubule-organising centres   Unknown
  2                 TUBG2     451      Ubiquitous                                                                                                       Important for nucleation and polarity of microtubules, mostly found in microtubule-organising centres   Unknown                                                                                                 
  δ                 --        TUBD1    453                                                                                                              Ubiquitous                                                                                              Sperm differentiation                                                                                   Decreased
  ε                 --        TUBE1    475                                                                                                              Majority of tissues                                                                                     Centrosome cycle                                                                                        Decreased

**Notes:** Data in this table were obtained from Uniprot (<http://www.uniprot.org>) and Proteinatlas (<http://www.proteinatlas.org>).
